Results 1 to 10 of about 298,087 (118)
Frontiers in Surgery, 2022 IntroductionNon-muscle-invasive bladder cancer (NMIBC) is a common and heterogeneous disease; many patients develop recurrent or progress to muscle-invasive disease.
Kelly Ward +4 more
doaj +1 more source
Genome Medicine, 2022 Background Three-quarters of bladder cancer patients present with early-stage disease (non-muscle-invasive bladder cancer, NMIBC, UICC TNM stages Ta, T1 and Tis); however, most next-generation sequencing studies to date have concentrated on later-stage ...
Anshita Goel +16 more
doaj +1 more source
European Urology Open Science, 2022 Background: Mutations in STAG2 cause complete loss of STAG2 protein in approximately one-third of non–muscle-invasive bladder cancers (NMIBCs). STAG2 protein expression is easily determined via immunohistochemistry (IHC) and published data suggest that ...
Naheema S. Gordon +9 more
doaj +1 more source
PD-L2 Is Constitutively Expressed in Normal and Malignant Urothelium
Frontiers in Oncology, 2021 The use of immune checkpoint blockade, in particular PD-1 and PD-L1 inhibitors, is now commonplace in many clinical settings including the treatment of muscle-invasive bladder cancer (MIBC).
Alexander C. Dowell +9 more
doaj +1 more source
European Urology Open Science, 2023 Enfortumab vedotin (EV) is an antibody-drug conjugate approved for the treatment of refractory advanced urothelial cancer. Cutaneous toxicity is well described but has not been correlated with response.
Evangelia Vlachou +6 more
doaj +1 more source
Properties of non-coding mutation hotspots as urinary biomarkers for bladder cancer detection
Scientific Reports, 2023 Mutations at specific hotspots in non-coding regions of ADGRG6, PLEKHS1, WDR74, TBC1D12 and LEPROTL1 frequently occur in bladder cancer (BC). These mutations could function as biomarkers for the non-invasive detection of BC but this remains largely ...
L. Baxter +14 more
doaj +1 more source
Oncology and Therapy, 2023 In this plain language podcast, highlights from the European Society for Medical Oncology (ESMO) Congress are discussed for a second year in a row, from the perspective of both a patient advocate and a healthcare professional.
Alex Filicevas, Thomas Powles
doaj +1 more source
Annals of Urologic Oncology, 2021 Introduction To evaluate the response of patients with high-risk bacillus Calmette-Guerin (BCG)–unresponsive non-muscle invasive bladder cancer (NMIBC) who we treated with intravesical CG0070, a conditionally replicating granulocyte macrophage colony ...
Evan Austin +3 more
doaj +1 more source
European Urology Open Science, 2023 Background: Grade of non–muscle-invasive bladder cancer (NMIBC) is an important prognostic factor for progression. Currently, two World Health Organization (WHO) classification systems (WHO1973, categories: grade 1–3, and WHO2004 categories: papillary ...
Irene J. Beijert +28 more
doaj +1 more source
Designing a Pragmatic Intervention to Help Improve the Bladder Cancer Patient Experience
Inquiry: The Journal of Health Care Organization, Provision, and Financing, 2021 Bladder cancer (BC) is the 10 th most common malignancy worldwide and the patient experience is found to be worse than that for patients diagnosed with other cancer types.
Agustina Bessa +26 more
doaj +1 more source